BA Neuschwander-Tetri, SH Caldwell - Hepatology, 2003 - ualberta.ca Fatty liver disease that develops in the absence of alcohol abuse is recognized
increasingly as a major health burden. This report summarizes the presentations
and discussions at a Single Topic Conference held September 20-22, 2002, ... Cited by 821 - Related articles - View as HTML - BL Direct - All 9 versions
RA DeFronzo, RE Ratner, J Han, DD Kim, MS … - Diabetes care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A triple-blind, placebo-controlled, 30-week study
at 82 US sites was performed with 336 randomized patients. In all, 272 patients
completed the study. The intent-to-treat population baseline was 53 ± 10 ... Cited by 635 - Related articles - All 6 versions
DM Kendall, MC Riddle, J Rosenstock, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg),
−0.6 ± 0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs.
placebo), yielding placebo-adjusted reductions of −1.0% (10 μg) and ... Cited by 542 - Related articles - All 11 versions
- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46
± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms,
respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA ... Cited by 453 - Related articles - BL Direct - All 13 versions
N Unwin, J Shaw, P Zimmet, KG Alberti - Diabetic medicine: a journal of the British Diabetic …, 2002 - ncbi.nlm.nih.gov A workshop was convened by the International Diabetes Federation to review the
latest information relating to the risks associated with impaired glucose
tolerance (IGT) and impaired fasting glycaemia (IFG) for future diabetes ... Cited by 399 - Related articles - All 3 versions
C Hadigan, C Corcoran, N Basgoz, B Davis, P … - Jama, 2000 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 345 - Related articles - BL Direct - All 4 versions
SH Caldwell, EE Hespenheide, JA Redick, JC … - The American journal of gastroenterology, 2001 - nature.com Troglitazone is a thiazolidinedione and peroxisome proliferator–activated
receptor gamma (PPAR ) ligand used to treat diabetes mellitus type II. Because
hyperinsulinemia may be a factor in nonalcoholic steatohepatitis (NASH), we ... Cited by 335 - Related articles - BL Direct - All 7 versions
- ►karolinskauniversitetssjukhuset.se [PDF] SR Salpeter, E Greyber, GA Pasternak, EE … - Archives of Internal Medicine, 2003 - archinte.highwire.org Methods A comprehensive search was performed to identify all comparative trials
or observational cohort studies published between January 1, 1959, and March 31,
2002, that evaluated metformin therapy, alone or in combination with other ... Cited by 317 - Related articles - BL Direct - All 16 versions
F de Vegt, JM Dekker, A Jager, E Hienkens, … - Jama, 2001 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Persons with ... Cited by 303 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org Y Miyazaki, A Mahankali, M Matsuda, L Glass, … - Diabetes Care, 2001 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 23 diabetic patients (age 30–70
years, BMI < 36 kg/m 2 ) who were being treated with a stable dose of
sulfonylurea were randomly assigned to receive either placebo (n = 11) or ... Cited by 271 - Related articles - BL Direct - All 7 versions
